Research On The Efficacy And Safety Of The Prescription Made Depending On Guo Ziguang’ S Clinical Experience On Acute Coronary Syndrome After PCI

Objective:To explore the efficacy and safety of the prescription made depending on Guo Ziguang’s clinical experience in the patients, suffering from acute coronary syndrome after PCI.Methods:Select the patients who are diagnosed with ACS and treated with PCI during the duration of hospital stay this time between May 2015 and February 2016 from cardiology of the Hospital. Screen out 40 patients. Taking the randomized, single-blind, control comparison method, we divide the 40 patients with ACS after PCI into two groups (N=20). The control group is given the western routine treatment, while the treatment group is given the western routine treatment plus the prescription made depending on Guo Ziguang’s clinical experience. The TCM syndrome scores,t he levels of platelet aggregation, the B-type natriuretic peptide(BNP), the main adverse cardiovascular events(MACE) and the hepatic and renal function were evaluated before and after the treatment.Results:Among the 40 patients, there is no any statistical difference (P<0.050) of two groups in baseline. (1) In the treatment group, the TCM syndrome scores before and after the one-month treatment are 17.40±1.875,6.20±2.567. In the control group, the TCM syndrome scores before and after the treatment are 16.90 ±2.553,8.90±2.573, There are statistically significant differences between the two groups after the treatment (average P＜0.050). (2) In the treatment group, the levels of platelet aggregation before and after the treatment are 48.45 ±10.118,18.45±6.747. In the control group, the levels of platelet aggregation before and after the treatment are 50.85±12.737,23.10± 6.980, There are statistically significant differences between the two groups after the treatment (average P＜0.050). (3) In the treatment group, the BNP before and after the treatment are 314.70±388.949,120.05±90.001. In the control group, the BNP before and after the treatment are 216.85±226.350,77.65± 56.498, there is no difference after the treatment between the treatment and control group (average P>0.050). (4) No major adverse cardiovascular events in both groups are found during the treatment. No liver and kidney dysfunction and adverse reactions in both groups are found.Conclusions:the prescription made depending on Guo Ziguang’s clinical experience can effectively reduce The TCM syndrome scores of the patients suffering from ACS after PCI. It can reduce the platelet aggregation of the above patients as well, It’s safe to them without causing liver and kidney dysfunction, increasing the major adverse cardiovascular events.But there is no sufficient evidence to reduce the BNP in the blood of the ACS patients after PCI.